Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury

Biochemical and Biophysical Research Communications

Volumn 405, Issue 1, 2011, Pages 79-84

  Goto, Hiromasa ^a   Nomiyama, Takashi ^a   Mita, Tomoya ^a   Yasunari, Eisuke ^a   Azuma, Kosuke ^a   Komiya, Koji ^a   Arakawa, Masayuki ^a   Jin, Wen Long ^a   Kanazawa, Akio ^a   Kawamori, Ryuzo ^a   Fujitani, Yoshio ^a   Hirose, Takahisa ^a   Watada, Hirotaka ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glucagon like peptide 1; Neointimal formation; Smooth muscle cells; Type 2 diabetes

Indexed keywords

EXENDIN 4; PLATELET DERIVED GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIAL WALL THICKENING; ARTICLE; BODY WEIGHT; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM INJURY; IN VITRO STUDY; INTIMA; MALE; METABOLIC PARAMETERS; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; TREATMENT DURATION;

ANIMALS; BODY WEIGHT; CELL PROLIFERATION; CELLS, CULTURED; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PEPTIDES; RATS; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; TUNICA INTIMA; VASCULAR SYSTEM INJURIES; VENOMS;

MURINAE; MUS; RATTUS;

EID: 79551488587     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.131     Document Type: Article

References (24)

1. Greig N.H., Holloway H.W., De Ore K.A., Jani D., Wang Y., Zhou J., Garant M.J., Egan J.M. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999, 42:45-50.
2. Kolterman O.G., Buse J.B., Fineman M.S., Gaines E., Heintz S., Bicsak T.A., Taylor K., Kim D., Aisporna M., Wang Y., Baron A.D. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003, 88:3082-3089.
3. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
4. Dupre J., Behme M.T., McDonald T.J. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J. Clin. Endocrinol. Metab. 2004, 89:3469-3473.
5. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141:1936-1941.
6. Horton E.S., Silberman C., Davis K.L., Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010, 33:1759-1765.
7. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
8. Timmers L., Henriques J.P., de Kleijn D.P., Devries J.H., Kemperman H., Steendijk P., Verlaan C.W., Kerver M., Piek J.J., Doevendans P.A., Pasterkamp G., Hoefer I.E. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 2009, 53:501-510.
9. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., Stolarski C., Shen Y.T., Shannon R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
10. Nikolaidis L.A., Mankad S., Sokos G.G., Miske G., Shah A., Elahi D., Shannon R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
11. Richter G., Feddersen O., Wagner U., Barth P., Goke R., Goke B. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol. 1993, 265:L374-L381.
12. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
13. Liu H., Dear A.E., Knudsen L.B., Simpson R.W. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol. 2009, 201:59-66.
14. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E1209-E1215.
15. Arakawa M., Mita T., Azuma K., Ebato C., Goto H., Nomiyama T., Fujitani Y., Hirose T., Kawamori R., Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037.
16. Doran A.C., Meller N., McNamara C.A. Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:812-819.
17. Ross R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 1995, 57:791-804.
18. The BARI Investigators Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J. Am. Coll. Cardiol. 2000, 35:1122-1129.
19. Nomiyama T., Nakamachi T., Gizard F., Heywood E.B., Jones K.L., Ohkura N., Kawamori R., Conneely O.M., Bruemmer D. The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J. Biol. Chem. 2006, 281:33467-33476.
20. Nomiyama T., Zhao Y., Gizard F., Findeisen H.M., Heywood E.B., Jones K.L., Conneely O.M., Bruemmer D. Deficiency of the NR4A neuron-derived orphan receptor-1 attenuates neointima formation after vascular injury. Circulation 2009, 119:577-586.
21. Arakawa M., Ebato C., Mita T., Hirose T., Kawamori R., Fujitani Y., Watada H. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Biochem. Biophys. Res. Commun. 2009, 390:809-814.
22. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006, 3:153-165.
23. Hattori Y., Jojima T., Tomizawa A., Satoh H., Hattori S., Kasai K., Hayashi T. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010, 53:2256-2263.
24. Danenberg H.D., Fishbein I., Gao J., Monkkonen J., Reich R., Gati I., Moerman E., Golomb G. Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002, 106:599-605.